• Zhonghua yi xue za zhi · Oct 2004

    [Telomerase antisense inhibition and chemotherapeutic combination treatments for the proliferation of endometrial cancer in vitro and in vivo].

    • Xue-Jun Chen, Wei Zheng, Li-Li Chen, Zhong-Bin Chen, and Sheng-Qi Wang.
    • Second Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China.
    • Zhonghua Yi Xue Za Zhi. 2004 Oct 17; 84 (20): 1721-5.

    ObjectiveTo investigate the antitumor effects of telomerase antisense oligodeoxynucleotide (AODN).MethodsHuman endometrial cancer cells of HEC-1A line were cultured at the concentrations of 0.8 and 1.6 micromol/L respectively and transfected with human telomerase AODN, as telomerase inhibitors, twice. 24, 48, 72, 96, and 128 hours after the first transfection MTT method was used to detect the absorbance at the wave length of 490 nm so as to determine the cell survival rate. HEC-1A cells were collected after transfection of 0.05, 0.1, 0.2, 0.4, and 0.8 micromol/L of AODN and the total DNA was extracted. Reverse transcription-polymerase chain reaction (RT-PCR) was used to examine the expression of hTERT mRNA. Telomeric repeat amplification protocol (TRAP)-ELISA was used to detect the activity of telomerase. HEC-1A cells were injected subcutaneously into the axillary fossae of Balb/c nude mice, Four days after when tumors were touchable the nude mice were divided into 5 groups to undergo intratumoral injection of high-dosage ADON (25 mg/kg, 1/d), low-dosage ADON (12.5 mg/kg, 1/d), cis-dichlorodiamine plastinum (DDP, cisplatin, 12.5 mg/kg, 1/d), AODN + DDP (AODN 12.5 mg/kg and DDP 5 microg/kg, 1/d alternatively), and normal saline respectively. The tumor size, tumor weight, and tumor relative volume were measured and calculated. Twenty-one days after the mice were killed and their organs were examined.ResultsAODN effectively and dose-dependently inhibited the growth of HEC-1A cells. There was a plateau of inhibition. The inhibition rate rose further 4 days after transfection. Five days after transfection the proliferation inhibition rate of AODN of the concentrations of 0.4, 0.8, and 1.6 microm were 46.35%, 65.22%, and 79.45% respectively. The relative inhibition rate of hTERT mRNA expression increased dose-independently along with the increase of concentration of transfected AODN. The tumor inhibition rate of nude mice were 34.20%, 89.21%, 79.82%, and 72.41% in the low-dosage AODN group, high-dosage AODN group, DDP group, and AODN + DDP group respectively. However, AODN began to show significant inhibitory effect 8 days after administration. The tumor inhibition rate of the AODN+DDP group was 72.4%, similar to those of the high dosage AODN and DDP groups (both P < 0.05). The telomerase activity in tumor of the AODN (25 mg/kg) group was 509 +/- 377, decreased by 87.23% in comparison with that of the control group (64 +/- 23, P < 0.05).ConclusionAntisesne oligonucleotide of hTERT effectively inhibits the abnormal activation of telomerase, thus the growth of endometrial cancer cells. Telomerase inhibitor may be a new strategy for chemotherapy or chemoprevention in endometrial cancer.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.